HC010 for advanced solid tumors: a safety and early efficacy study
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced cancer (solid tumor) that has not responded to standard treatments or no standard treatment exists.
- You are able to do your daily activities with little or no help (ECOG score 0 or 1).
- You have not had certain prior cancer treatments within the last 2–4 weeks, including immunotherapy targeting PD-1/PD-L1/CTLA-4/VEGF.
- You do not have active brain metastases, serious infections, autoimmune disease, or unstable heart/lung/liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests a new drug called HS-20105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called H1710 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if H1710 is safe and effective.
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.